Navigation Links
Animas' Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Date:2/28/2013

WEST CHESTER, Pa., Feb. 28, 2013 /PRNewswire/ -- Animas Corporation announced today positive results from the second phase of human clinical trials of a first-generation, closed-loop insulin delivery system in development, designed to predict a rise or fall in blood glucose and correspondingly increase, decrease, suspend and resume insulin delivery. The data were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Paris, France.

The feasibility study of the predictive Hypoglycemia-Hyperglycemia Minimizer (HHM) System* in development was conducted in 20 adults with Type 1 diabetes and designed to investigate the System's ability to adjust insulin dosing to proactively mitigate hypoglycemia and hyperglycemia. The study, which was the first conducted in humans to investigate the configuration of the predictive algorithm, revealed differences in the algorithm's insulin-dosing characteristics and provided insights into the sensitivity of the System. The results also indicated that the System reduced insulin delivery in advance of hypoglycemia and triggered timely warnings. The study was conducted by Animas Corporation in partnership with leading academic research institutions, including the University of California, Santa Barbara; Sansum Diabetes Research Institute; and the Center for Diabetes Technology at the University of Virginia.

"We are encouraged by these results, which strengthen our understanding of the complex algorithms required of a closed-loop insulin delivery system and further our confidence in this technology platform," said Ramakrishna Venugopalan , Director, Research & Development at Animas Corporation.  "The scope of this study also reflects our commitment to create innovative and robust solutions for people living with diabetes."

Animas began collaborating with industry, academia and advocacy organizations, including the JDRF (formerly the Juvenile Diabetes Research Foundation), in 2010. After receiving Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in 2011, researchers began the first human clinical feasibility studies for the development of a closed-loop insulin delivery system. Together with these key partners, Animas continues to work toward developing such an automated system to help people living with Type 1 diabetes better control their disease. 

"We are encouraged by the results and progress Animas has made in the first stage of development of a closed-loop insulin delivery system," said Aaron Kowalski , Ph.D., Vice President of Treatment Therapies Research at JDRF.  "A predictive system that cannot only detect, but can predict blood sugar levels and make automatic adjustments to insulin delivery would be a major advance for people with Type 1 diabetes."

* The HHM System includes a continuous subcutaneous insulin infusion pump, a continuous glucose monitor (CGM) and a control algorithm used to predict changes in blood glucose. 

About the Clinical Study
The study investigated the effect of a fundamental algorithm parameter on the quantitative insulin-dosing characteristics of the System. The parameter, known as the "aggressiveness factor," affects how readily the algorithm adjusts insulin delivery in response to glucose fluctuations. This is the first study in humans to investigate tuning such an algorithm parameter. The results demonstrated differences in the algorithm's insulin-dosing characteristics based on three aggressiveness factors and reinforced the importance of investigating the sensitivity of the System to its key parameters.

The study also investigated the predictive, proactive methods by which the System mitigates hypoglycemia, especially as compared to reactive, threshold-based systems. In particular, two predictive hypoglycemia safeguards of the System were investigated: its ability to decrease/suspend insulin delivery before a hypoglycemic threshold is reached, and its ability to trigger timely alerts for imminent hypoglycemia. The results indicated that the System reduced insulin delivery in advance of breaches of a hypoglycemic threshold and triggered timely warnings for imminent hypoglycemia.

Regarding general glucose control, the System demonstrated promising results, keeping glucose levels at an average of 133 mg/dL for the entire cohort. On average, 82.8 percent of the closed-loop time was spent at glucose levels between 70-180 mg/dL, and little time (3.4 percent) was spent at levels below 70 mg/dL. There were no safety concerns, including diabetic ketoacidosis or severe hypoglycemia.

About Animas Corporation
As part of the Johnson & Johnson Family of Companies, Animas is dedicated to creating a world without limits for people with diabetes through a wide range of products, including the OneTouch® Ping® Glucose Management System, Animas® Vibe™ insulin pump and CGM system and the Animas® 2020 insulin pump.  Animas, from the Latin word meaning "true inner self or soul," has been committed since 1996 to meeting individual patient needs through the development of life-performance technology and customer service 24 hours a day, 7 days a week, 365 days a year. To learn more about Animas, visit http://www.animas.com/.  


'/>"/>
SOURCE Animas Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
2. ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
3. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
4. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
5. Successful Inspection by the FDA of ENCO Pharmaceutical Developments Cary, NC Facility
6. Australian Government Invests in Detection and Management of Blinding Eye Disease and Diabetes Through Intelligent High Resolution Retinal Camera Development by Vision CRC
7. HKTU Announces Development of a New Male Enhancement Supplement
8. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
9. Xenon Announces Appointment of EVP, Research & Development
10. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
11. Varian Medical Systems Supports Program to Tap Brain Power of Research and Development Community in Russia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... January 24, 2017 Analysis of the Liquid ... Liquid Biopsies - our new study reveals trends, R&D progress, ... If you are involved in this sector you must read this ... revenues streams to 2027, assessing data, trends, opportunities and business prospects ... Discover How ...
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... 2017   Keneric Healthcare , a medical ... patient care products, today announced their partnership with ... reach of both companies by leveraging their clinical ... Angelini Pharma Inc . is ... Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ wound ...
Breaking Medicine Technology:
(Date:1/24/2017)... Hills Estates, CA (PRWEB) , ... January 24, 2017 , ... ... performance at studies, work, athletics or even in relationships. Course offered by Dr. ... fee is necessary due to limited seating and the many hands-on experiences. ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
(Date:1/24/2017)... TX (PRWEB) , ... January 24, 2017 , ... Bellus ... the company’s team of medical experts. In his new role Dr. Dobke will provide ... , Dr. Dobke is the Head of Plastic Surgery and Associate Professor of ...
(Date:1/24/2017)... Chapel Hill, N.C. (PRWEB) , ... January 24, ... ... the Trump Administration is the focus of a new report from the ... Carolina Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The results ... news for everyone and particularly good news for prostate cancer patients: incidents of cancer ... , According to the report the cancer death rate has dropped from its peak ...
Breaking Medicine News(10 mins):